Merck & Co: Positive Oncology Research Data Presented at ASCO Congress
This article was created with the help of artificial intelligence.
Key Takeaways
- Merck & Co presented new data on solid tumors at the ASCO Congress on June 5, 2026
- The cancer drug Keytruda continues to show positive results in oncology
- Other agents in the Merck pipeline are designed to address the future patent expiration of Keytruda
- The biopharma industry recorded $106 billion in M&A deals globally by early June 2026
Merck & Co presented new cancer research study data at the annual ASCO Congress (American Society of Clinical Oncology) on June 5, 2026. The data on solid tumors underscore the strength of the US pharmaceutical company in oncology. The cancer drug Keytruda continues to show positive results, while other agents in the Merck pipeline are designed to offset the future loss of patent protection for Keytruda.
Keytruda remains central to Merck oncology
Keytruda, an immune checkpoint inhibitor used for various cancer types, remains a central revenue driver for Merck & Co. The data on solid tumors presented at the ASCO Congress show that the drug continues to demonstrate its effectiveness in this area. Solid tumors are fixed cancer growths that differ from blood cancers and account for approximately 90 percent of all cancer cases.
However, patent protection for Keytruda will expire in the coming years, prompting the company to work on successor products early on. According to the information available, other agents in the Merck pipeline are specifically designed to fill this gap.
Biopharma industry with high M&A activity
In the broader industry context, the biopharma sector is experiencing significantly increased acquisition activity in 2026. According to a CNBC report, M&A transactions reached a volume of $106 billion globally over 201 deals by early June 2026. This puts the industry on track for its strongest full year since the pre-pandemic peak in 2019. Among the most active buyers are Merck & Co, Gilead, and Eli Lilly.
The high consolidation activity reflects the pressure pharmaceutical companies face from expiring patents and the need for new product pipelines. Acquisitions allow established corporations to strategically integrate innovative drugs and technologies.
Positive data also for Moderna partnership
On June 5, 2026, Moderna and Merck also presented positive long-term data on a personalized mRNA cancer vaccine. The partnership between biotechnology company Moderna and Merck aims to develop individualized therapies based on mRNA technology. The data presented indicate progress in this promising approach.
The ASCO Congress is considered the most important platform for presenting new cancer research findings and attracts thousands of oncologists and researchers annually. The data presented there often influence the further clinical development of drugs and provide insight into future approvals.